The effect of specific C5aR antagonists in decreasing the pathology and improving clinical symptoms in animal models of other neurodegenerative diseases[26,27] suggests that C5a-CD88 interaction accelerates disease and can be a therapeutic target. This evidence concerns the gene C5AR1 and neurodegenerative disease.